As biosimilars hit, EU pharma warns against blanket prescribing

LONDON (Reuters) - European drugmakers, faced with increasing competition from cut-price copies of complex biotech drugs, cautioned doctors on Thursday to take care when switching patients from an established product to a so-called biosimilar version.